Skip to main content

Could CBD Help Ease Symptoms Of IBS? Here's What We Know, Based On The Evidence

Cannabidiol (or CBD), a nonpsychoactive derivative of marijuana or hemp, is thought to ease everything from anxiety to chronic pain, but if you’ve wondered if it could help treat your inflammatory bowel disease or irritable bowel syndrome, the answer is, well, perhaps.

While the two conditions are very similar, there are distinct differences in what we know about their causes and symptoms and how CBD can be used to alleviate them, explained Rachna Patel, MD, a California-licensed physician and CBD expert.

Inflammatory bowel disease (IBD) is an autoimmune issue in which the body attacks the GI tract, often diagnosed as Crohn’s disease or ulcerative colitis. The symptoms include severe stomach cramps and nausea and, more rarely, vomiting and poor appetite. The cause of irritable bowel syndrome (IBS) isn’t as well understood, but it shares many of the symptoms of inflammatory bowel disease, as well as a few more, including alternating episodes of diarrhea and constipation.

Can CBD Help Soothe Your Symptoms?

“IBS can be difficult to treat,” said Michael Verbora, MBA, MD, CCFP, the chief medical officer for Ontario-based Aleafia, a medical cannabis care facility. If standard treatments — including probiotics, dietary changes, and reduction of stress — have failed to manage your symptoms, CBD oil may be an option, he noted.

Dr. Verbora sees about 200 patients who suffer from IBS, with symptoms ranging from mild to severe. Most of those patients use CBD oil, and some use a formula containing small amounts of tetrahydrocannabinol (THC), the only compound in cannabis that’s mind-altering. “Out of all treatments my patients have tried for IBS, the majority find cannabis to be the most beneficial,” Dr. Verbora told POPSUGAR.

Likewise, Dr. Patel’s patients with IBD seem to find more relief from their symptoms with products derived from marijuana, rather than hemp. While the plants are very similar, there’s a specific legal distinction: unlike cannabis, hemp can contain only a very small percentage of THC.

Still, “this is only anecdotal evidence, as we need more research to understand why CBD works and what doses and ingredients work best,” Dr. Verbora said. For now, one study found that IBS and related conditions may be caused by a deficiency in naturally occurring cannabinoids within the body, which makes potentially treating them with cannabis-based medicine not a far-off conclusion.

Should You Try It?

While there’s no research to confirm whether CBD is an effective treatment for stomach issues, it is considered to be safe by the World Health Organization, meaning there’s no physical harm in trying it.

“The biggest risk to patients is that they spend a few hundred dollars,” Dr. Verbora said, with no guarantee that it will work. Still, “cannabis is an option for people living with IBS symptoms that are not well-managed, and you should seek out a physician’s help in trying it, if you’re interested.”

A doctor can help you determine the right product and dosage to start, but Dr. Patel recommends keeping tabs on your intake as well. “Track the exact amount of milligrams you’re taking of CBD and THC, and the effect it has on your symptoms, as well as any side effects, and adjust accordingly,” she said. That means you should check that CBD oil is properly labeled before you buy.

Image Source: POPSUGAR Photography / Dominique Astorino

Original Article Source: https://www.popsugar.com/fitness/CBD-Oil-IBS-45365792

Comments

Post a Comment

Popular posts from this blog

Could CBD Lead To The Development Of Safer Antipsychotic Medications?

Antipsychotic medications are important for managing a number of different psychiatric ailments, including bipolar disorders, schizophrenia, and even dementia. These drugs can greatly improve the manageability of symptoms that often distort one’s experience of reality. They can also create major mood disruptions and lead to a number of behavioral and emotional difficulties. Antipsychotic and anti-psychosis medications can be life-changing for people with such disorders, enabling them to live more normal and manageable lives without their symptoms taking over. These drugs work by regulating neurotransmitters in the brain so that naturally occurring imbalances and dysfunctions no longer disrupt mental and emotional processes. Often, reaching this outcome is much easier said than done; it can take a lot of time to find courses and combinations of treatments that work. It’s sometimes necessary to make adjustments to find the right balance for the individual and it’s not unusual for outc...
Post a Comment
Read more

A Dozen US Governors Ask Congressional Leaders To Back Federal Marijuana Reform

A bipartisan coalition of 12 governors from states that have legalized medical or recreational cannabis  sent a letter to congressional leaders, asking for their support in getting a major marijuana reform bill through the U.S. House and Senate. The governors of California, Colorado, Maryland, Massachusetts, Nevada, New York, North Dakota, Oregon, Pennsylvania, Utah, Vermont and Washington state are backing  the STATES Act  – which would codify in federal law that marijuana regulations are to be left to the states instead of the federal government – while also seeking protections on banking and tax issues for the MJ industry. “The STATES Act is not about whether marijuana should be legal or illegal; it is about respecting the authority of states to act, lead and respond to the evolving needs and attitudes of their citizens,” the governors wrote. The letter also expressed support for the SAFE Banking Act , which was approved in March by a House committee. Tha...
Post a Comment
Read more

Cannabis Watch: Canopy Growth To Book Charge Of Up To $568 Million As Marijuana Restructuring Continues

Canopy Growth Corp. said early Thursday it was halting a range of operations across three continents and expects its restructuring plans to result in a charge of up to C$800 million (567.9 million) in the fiscal fourth quarter. U.S.-traded shares US:CGC CA:WEED of the cannabis company fell 1.9% in afternoon trading. Canopy said it was selling operations in Africa, curtailing cultivation of hemp in the U.S. and Columbia, and shutting down an indoor production facility in Canada. The announcement will result in 85 job cuts, the company said. “When I arrived at Canopy Growth in January, I committed to conducting a strategic review in order to lower our cost structure and reduce our cash burn,” Canopy Chief Executive David Klein said in a statement. Read: As cannabis industry stays largely quiet on coronavirus, this CEO has been sounding the alarm Canopy’s restructuring announcement was expected by investors, Cowen analyst Vivien Azer wrote in a note to clients Thursday. Azer rate...
Post a Comment
Read more